SLC45A2 and prostate cancer: The high positive prediction rates for MAN2A1-FER (88.2%), SLC45A2-AMACR (75%) and Pten-NOLC1 (90.9%) between blood samples and the primary prostate cancer samples suggests that the source of the fusion transcripts in the blood samples is likely prostate cancer.